Ruishi Technology

Ruishi Technology (睿视科技) is an ophthalmic AR/VR medical device company founded in 2017 that specializes in myopia prevention and control for children and adolescents . Its core product is the myopia-prevention "远像光屏" (distant-image optical screen), developed under the scientific leadership of chief scientist Wang Ningli, a member of the Chinese Academy of Engineering and former president of the Chinese Ophthalmological Society, and chief optical advisor Wang Yongtian, a professor at Beijing Institute of Technology .

The company has raised multiple rounds from BlueRun Ventures, which led its Series A and continued to invest in its Series A+ . In 2023, Ruishi Technology closed a 100-million-RMB Series A+ round led by Innovation Works, with follow-on from Botanee and existing shareholders including BlueRun Ventures and Yaojin Capital . More recently, in mid-2025, it secured additional tens of millions of RMB in fresh funding, with existing shareholder Innovation Works continuing to add to its position . The company is now positioning itself around an AI-driven "light-eye-brain" intelligent therapeutic closed-loop system that integrates optical stimulation, neural modulation, and AI feedback, expanding from myopia intervention toward broader digital eye-brain health management .